Healthcare, Pharma & Life Sciences

ABMS Names Record 23 Scholars for AI, Burnout Research in 2026-27

Image
ABMS Names Record 23 Scholars for AI, Burnout Research in 2026-27

Chicago – September 18, 2026 -- The American Board of Medical Specialties (ABMS) has selected a record 23 physicians for its 2026-2027 Scholars Program, each receiving a $15,000 financial award to conduct research on board certification, artificial intelligence in clinical assessment, and physician burnout.

ABMS expands its scholar cohort to a record size since the program's 2014 launch

The one-year, part-time initiative supports early-career physicians and researchers focused on initial and continuing board certification. Recipients remain at their home institutions, work with self-selected mentors, and join monthly virtual sessions with peers, mentors, Member Board leaders and program alumni. Greg Ogrinc, MD, ABMS Senior Vice President for Certification Standards and Programs, said the rising volume of applicants reflects growing interest in research addressing certification and physician assessment.

PSMA Connect, HealthIQ Solutions Launch Joint GPO-RPM Provider Alliance

Image
PSMA Connect, HealthIQ Solutions Launch Joint GPO-RPM Provider Alliance

Atlanta and Wilmington, Del. – September 18, 2026 -- PSMA Connect, a national Healthcare Group Purchasing Organization, has formed a strategic alliance with HealthIQ Solutions to bundle volume-discounted medical supply contracts with turn-key remote patient care programs for providers nationwide.

Alliance pairs supply chain discounts with zero-cost remote monitoring rollouts

The partnership gives medical practices and health systems access to PSMA Connect's discounted manufacturer contracts covering medical-surgical supplies, capital equipment, pharmaceuticals and vaccines. Simultaneously, providers can deploy HealthIQ Solutions' Remote Patient Monitoring (RPM), Chronic Care Management (CCM) and Advanced Primary Care Management (APCM) programs with no upfront costs, using cellular- and Bluetooth-connected devices and automated compliance tracking.

MoleculeMind's QuantaMind AI Simulates Full Enzyme Reactions, Hits SOTA Speed

Shanghai – September 18, 2026 -- MoleculeMind, an AI-native bioengineering infrastructure company, has had research on its reactive atomistic modeling platform QuantaMind published in Science Advances, demonstrating Density Functional Theory (DFT)-level accuracy in simulating 10,000-atom biomolecular systems over tens-of-nanosecond timescales.

QuantaMind becomes first platform to simulate a complete enzyme reaction cycle

The study shows QuantaMind enabling AI to observe the full atomic-scale process of proton transfer, bond breaking and formation, and complete enzyme catalytic cycles. In industrial deployments, the platform has been scaled further to model reactive systems comprising hundreds of thousands of atoms.

Pipette Calibration Market to Hit $834.8M by 2031 as Transcat Drives M&A

Image
Pipette Calibration Market to Hit $834.8M by 2031 as Transcat Drives M&A

Delray Beach, Fla. – September 18, 2026 -- The global pipette calibration services market is projected to more than double to USD 834.8 million by 2031 from USD 383.2 million in 2026, a 16.9% compound annual growth rate, according to MarketsandMarkets.

North America controls half of global demand as regulatory pressure mounts

North America held a 50.6% share of the pipette calibration services market in 2025, underpinned by dense pharmaceutical and biotechnology infrastructure, federal biomedical research funding, and strict laboratory equipment qualification requirements. Thermo Fisher Scientific, Eppendorf, and Sartorius operate significant service footprints across the region, supporting clinical labs, academic institutions, and drug manufacturers requiring traceable measurement accuracy.

Alveo, AGBL Ink Deal to Expand Bird Flu Testing Across Africa, Asia

Image
Alveo, AGBL Ink Deal to Expand Bird Flu Testing Across Africa, Asia

Alameda – September 18, 2026 -- Alveo Technologies has signed a distribution agreement with Alliance Global (AGBL) to deploy its on-farm avian influenza diagnostic across Africa, Central Asia and select Eastern Mediterranean countries, as global bird flu outbreaks have infected at least 633 million domestic birds worldwide, including more than 208 million in the U.S. alone.

Alveo Sense Poultry gains distribution rights across three continents

Under the deal, AGBL secures rights to distribute Alveo's palm-sized molecular diagnostic platform to farmers, integrators and public health officials throughout Africa, Central Asia and portions of the Eastern Mediterranean region. AGBL operates as a biomedical distribution group with offices in more than 17 countries across the Middle East, Africa and Asia.

NCCN, Pfizer Fund Four Quality Projects to Close mPCA Care Gaps

Image
NCCN, Pfizer Fund Four Quality Projects to Close mPCA Care Gaps

Plymouth Meeting, Pa. – September 18, 2026 -- The National Comprehensive Cancer Network (NCCN) Oncology Research Program has awarded funding for four quality improvement projects targeting metastatic prostate cancer (mPCA) care, backed by Pfizer Global Medical Grants (GMG).

Four institutions receive two-year grants to standardize mPCA treatment protocols

The selected projects, each set for completion within two years, will run at UT Southwestern Simmons Comprehensive Cancer Center, Georgetown University, Northwestern University's Robert H. Lurie Comprehensive Cancer Center, and Moffitt Cancer Center. Changchuan (Charles) Jiang, MD, at UT Southwestern will lead a biomarker action-loop initiative within a major U.S. safety-net cancer program. Paul Leger, MD, at Georgetown will implement multilevel interventions across the Medstar Health Network under the I-CARE PCA project.

BioMarin Adds Bristol Myers Squibb Research Chief Robert Plenge to Board

Image
BioMarin Adds Bristol Myers Squibb Research Chief Robert Plenge to Board

San Rafael, Calif. – September 18, 2026 -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) has appointed Robert Plenge, M.D., Ph.D., to its Board of Directors, effective September 18, 2026.

Plenge brings nine-site global research oversight from Bristol Myers Squibb

Dr. Plenge currently serves as Executive Vice President, Chief Research Officer and Head of Research at Bristol Myers Squibb, directing scientific operations across nine research sites worldwide. He joined the company in November 2019 through its acquisition of Celgene Corp., where he had led the immunology and inflammation portfolio in research and early development.

EMD Serono Buys PostEra's AI-Designed Oral Fertility Drug Programs

Image
EMD Serono Buys PostEra's AI-Designed Oral Fertility Drug Programs

Boston – September 17, 2026 -- EMD Serono, Inc., the healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and Canada, has acquired two preclinical fertility drug programs from PostEra, a biotech firm built on artificial intelligence-driven small molecule discovery.

PostEra's Proton platform generated oral agonists targeting two hard-to-drug fertility receptors

The acquired programs target the follicle-stimulating hormone receptor (FSHR) and the luteinizing hormone/choriogonadotropin receptor (LHCGR), both used over two years by PostEra's AI platform Proton to design small molecule candidates for reproductive endocrinology. FSHR agonists were developed for ovarian stimulation in in vitro fertilization (IVF), while LHCGR agonists target male infertility and ovulation triggering in IVF protocols.

Acurx Poster Shows Ibezapolstat Beats Vancomycin in C. diff-VRE Co-Cultures

Image
Acurx Poster Shows Ibezapolstat Beats Vancomycin in C. diff-VRE Co-Cultures

Staten Island, N.Y. – September 17, 2026 -- Acurx Pharmaceuticals (NASDAQ: ACXP) presented new in vitro data showing its lead antibiotic ibezapolstat achieved a 5.51-log reduction against Clostridioides difficile in co-culture with vancomycin-resistant Enterococcus (VRE), significantly outperforming vancomycin (p=0.0112), the current standard of care.

The poster, presented by Dr. Eugenie Bassères of the University of Houston College of Pharmacy, was unveiled at the 9th International C. difficile Symposium in Bled, Slovenia, held September 8-10, 2026.

VRE strains showed high-level resistance to vancomycin but not to ibezapolstat

All tested VRE strains exhibited vancomycin resistance with minimum inhibitory concentrations (MIC) above 128 μg/mL. Ibezapolstat and fidaxomicin maintained equivalent, lower susceptibility thresholds of 2-16 μg/mL.

FDA Grants Breakthrough Therapy Status to Armata's AP-SA02 Phage Drug

Image
FDA Grants Breakthrough Therapy Status to Armata's AP-SA02 Phage Drug

Los Angeles – September 17, 2026 -- The U.S. Food and Drug Administration has granted Breakthrough Therapy designation to Armata Pharmaceuticals' AP-SA02, an intravenous multi-phage candidate for complicated Staphylococcus aureus bacteremia, stacking the designation atop existing Fast Track and Qualified Infectious Disease Product status.